RBC Capital Maintains Outperform on Knight Therapeutics, Raises Price Target to C$8.5

RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:GUD) with a Outperform and raises the price target from C$8 to C$8.5.